REFRACTORY LUPUS NEPHRITIS
Clinical trials for REFRACTORY LUPUS NEPHRITIS explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY LUPUS NEPHRITIS trials appear
Sign up with your email to follow new studies for REFRACTORY LUPUS NEPHRITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immune cell shot aims to tame tough lupus cases
Disease control Recruiting nowThis early-phase trial tests whether adding NK cells (a type of immune cell) to the standard drug rituximab can safely help people with severe lupus or lupus-related kidney disease. The study will enroll 18 adults in China and focus on safety and signs of disease improvement. It …
Matched conditions: REFRACTORY LUPUS NEPHRITIS
Phase: PHASE1 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Engineered immune cells take on lupus, scleroderma, and Sjogren's
Disease control Recruiting nowThis study tests a new treatment using a patient's own immune cells, modified to target and attack harmful cells in three severe autoimmune diseases: lupus nephritis, systemic sclerosis, and Sjogren's syndrome with pulmonary hypertension. About 45 adults will receive a single inf…
Matched conditions: REFRACTORY LUPUS NEPHRITIS
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could CAR-T cells tame tough autoimmune diseases?
Disease control Recruiting nowThis early-stage trial is testing a new treatment made from umbilical cord blood cells, called CD19-BCMA CAR-T cells, in 45 people with severe lupus, scleroderma, or Sjogren's syndrome with lung complications. The main goal is to check safety, especially serious side effects with…
Matched conditions: REFRACTORY LUPUS NEPHRITIS
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
CAR T-Cell therapy: what happens years later?
Knowledge-focused Recruiting nowThis study follows about 70 people who have already received KYV-101, a CAR T-cell therapy, for autoimmune diseases like lupus and multiple sclerosis. Researchers will monitor participants for up to 15 years to track any delayed side effects, new cancers, or other health problems…
Matched conditions: REFRACTORY LUPUS NEPHRITIS
Sponsor: Kyverna Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC